Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebentafusp in Advanced Non-Ocular Melanoma
NCT05549297Phase 3Recruiting
- Sponsor
- Immunocore
- Start
- Dec 2022
- Primary completion
- Mar 2028
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of tebentafusp in melanoma, sponsored by Immunocore. Primary endpoint: Overall Survival at 4 years. Started Dec 2022; status: recruiting.
02
Drugs
tebentafusp
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05549297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549297.